| Heather Campbell, APRN | |
|
3725 W 4100 South, West Valley City, UT 84120 | |
| (801) 965-3600 | |
| (801) 965-3526 |
| Full Name | Heather Campbell |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 19 Years |
| Location | 3725 W 4100 South, West Valley City, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427080670 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 1997684405 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jordan Valley Medical Center | West jordan, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Catholic Health Initiatives Colorado | 8022927342 | 998 |
News Archive
BioClinica®, Inc.,, a global provider of clinical trial management services, today announced that GlaxoSmithKline LLC ("GSK") has signed a multi-year enterprise technology agreement to deploy BioClinica's Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.
Led by Dr Ben Lehner, group leader at the EMBL-CRG Systems Biology Unit and ICREA and AXA Professor, together with Dr Tanya Vavouri from the Josep Carreras Leukaemia Research Institute and the Institute for Health Science Research Germans Trias i Pujol, the researchers noticed that the impact of environmental change can be passed on in the genes for many generations while studying C. elegans worms carrying a transgene array - a long string of repeated copies of a gene for a fluorescent protein that had been added into the worm genome using genetic engineering techniques.
A common medication that reduces bleeding could be a treatment for bleeding stroke, particularly if administered quickly, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Canadians are increasingly being forced to choose between their personal health and their financial future, according to a study released today by the Canadian Council for Integrated Healthcare.
Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer, July 3-7 in Amsterdam, The Netherlands.
› Verified 6 days ago
| Entity Name | Physician Group Of Utah Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477676930 PECOS PAC ID: 8022032234 Enrollment ID: O20060113000886 |
News Archive
BioClinica®, Inc.,, a global provider of clinical trial management services, today announced that GlaxoSmithKline LLC ("GSK") has signed a multi-year enterprise technology agreement to deploy BioClinica's Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.
Led by Dr Ben Lehner, group leader at the EMBL-CRG Systems Biology Unit and ICREA and AXA Professor, together with Dr Tanya Vavouri from the Josep Carreras Leukaemia Research Institute and the Institute for Health Science Research Germans Trias i Pujol, the researchers noticed that the impact of environmental change can be passed on in the genes for many generations while studying C. elegans worms carrying a transgene array - a long string of repeated copies of a gene for a fluorescent protein that had been added into the worm genome using genetic engineering techniques.
A common medication that reduces bleeding could be a treatment for bleeding stroke, particularly if administered quickly, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Canadians are increasingly being forced to choose between their personal health and their financial future, according to a study released today by the Canadian Council for Integrated Healthcare.
Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer, July 3-7 in Amsterdam, The Netherlands.
› Verified 6 days ago
| Entity Name | Utah Regional Hospitalists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962821223 PECOS PAC ID: 4789807165 Enrollment ID: O20140604000236 |
News Archive
BioClinica®, Inc.,, a global provider of clinical trial management services, today announced that GlaxoSmithKline LLC ("GSK") has signed a multi-year enterprise technology agreement to deploy BioClinica's Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.
Led by Dr Ben Lehner, group leader at the EMBL-CRG Systems Biology Unit and ICREA and AXA Professor, together with Dr Tanya Vavouri from the Josep Carreras Leukaemia Research Institute and the Institute for Health Science Research Germans Trias i Pujol, the researchers noticed that the impact of environmental change can be passed on in the genes for many generations while studying C. elegans worms carrying a transgene array - a long string of repeated copies of a gene for a fluorescent protein that had been added into the worm genome using genetic engineering techniques.
A common medication that reduces bleeding could be a treatment for bleeding stroke, particularly if administered quickly, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Canadians are increasingly being forced to choose between their personal health and their financial future, according to a study released today by the Canadian Council for Integrated Healthcare.
Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer, July 3-7 in Amsterdam, The Netherlands.
› Verified 6 days ago
| Entity Name | Santibanez Aguirre Slc Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609334911 PECOS PAC ID: 0345582383 Enrollment ID: O20190423002734 |
News Archive
BioClinica®, Inc.,, a global provider of clinical trial management services, today announced that GlaxoSmithKline LLC ("GSK") has signed a multi-year enterprise technology agreement to deploy BioClinica's Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.
Led by Dr Ben Lehner, group leader at the EMBL-CRG Systems Biology Unit and ICREA and AXA Professor, together with Dr Tanya Vavouri from the Josep Carreras Leukaemia Research Institute and the Institute for Health Science Research Germans Trias i Pujol, the researchers noticed that the impact of environmental change can be passed on in the genes for many generations while studying C. elegans worms carrying a transgene array - a long string of repeated copies of a gene for a fluorescent protein that had been added into the worm genome using genetic engineering techniques.
A common medication that reduces bleeding could be a treatment for bleeding stroke, particularly if administered quickly, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Canadians are increasingly being forced to choose between their personal health and their financial future, according to a study released today by the Canadian Council for Integrated Healthcare.
Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer, July 3-7 in Amsterdam, The Netherlands.
› Verified 6 days ago
| Entity Name | Catholic Health Initiatives Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942903562 PECOS PAC ID: 8022927342 Enrollment ID: O20230615001995 |
News Archive
BioClinica®, Inc.,, a global provider of clinical trial management services, today announced that GlaxoSmithKline LLC ("GSK") has signed a multi-year enterprise technology agreement to deploy BioClinica's Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.
Led by Dr Ben Lehner, group leader at the EMBL-CRG Systems Biology Unit and ICREA and AXA Professor, together with Dr Tanya Vavouri from the Josep Carreras Leukaemia Research Institute and the Institute for Health Science Research Germans Trias i Pujol, the researchers noticed that the impact of environmental change can be passed on in the genes for many generations while studying C. elegans worms carrying a transgene array - a long string of repeated copies of a gene for a fluorescent protein that had been added into the worm genome using genetic engineering techniques.
A common medication that reduces bleeding could be a treatment for bleeding stroke, particularly if administered quickly, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Canadians are increasingly being forced to choose between their personal health and their financial future, according to a study released today by the Canadian Council for Integrated Healthcare.
Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer, July 3-7 in Amsterdam, The Netherlands.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heather Campbell, APRN 3725 W 4100 South, West Valley City, UT 84120 Ph: (801) 965-3600 | Heather Campbell, APRN 3725 W 4100 South, West Valley City, UT 84120 Ph: (801) 965-3600 |
News Archive
BioClinica®, Inc.,, a global provider of clinical trial management services, today announced that GlaxoSmithKline LLC ("GSK") has signed a multi-year enterprise technology agreement to deploy BioClinica's Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.
Led by Dr Ben Lehner, group leader at the EMBL-CRG Systems Biology Unit and ICREA and AXA Professor, together with Dr Tanya Vavouri from the Josep Carreras Leukaemia Research Institute and the Institute for Health Science Research Germans Trias i Pujol, the researchers noticed that the impact of environmental change can be passed on in the genes for many generations while studying C. elegans worms carrying a transgene array - a long string of repeated copies of a gene for a fluorescent protein that had been added into the worm genome using genetic engineering techniques.
A common medication that reduces bleeding could be a treatment for bleeding stroke, particularly if administered quickly, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Canadians are increasingly being forced to choose between their personal health and their financial future, according to a study released today by the Canadian Council for Integrated Healthcare.
Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer, July 3-7 in Amsterdam, The Netherlands.
› Verified 6 days ago
Danielle Renee Puri, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3448 West 3200 South, West Valley City, UT 84119 Phone: 801-359-2256 Fax: 801-364-4392 | |
Dr. Valerie Rebekah Birdsall, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1906 W 3600 S, West Valley City, UT 84119 Phone: 801-973-9675 | |
Kristen Gulock, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2965 W 3500 S, West Valley City, UT 84119 Phone: 801-965-3424 | |
Tonya Wright, PMHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 4052 W Pioneer Pkwy, West Valley City, UT 84120 Phone: 801-386-1250 | |
Mrs. Mary D Joyce, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3730 W 4700 S, West Valley City, UT 84118 Phone: 801-581-2121 | |
Ms. Carina Lesser, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3725 W 4100 S, West Valley City, UT 84120 Phone: 801-965-3600 Fax: 801-965-3740 | |
Jonathan Rohwer, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 4701 W 2100 S, West Valley City, UT 84120 Phone: 801-974-3382 |